Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amicus Reports Positive Preliminary Data On Plicera For Gaucher Disease

This article was originally published in The Pink Sheet Daily

Executive Summary

Amicus and partner Shire hope to grab a share of the $1 billion market now dominated by Genzyme’s Cerezyme.

You may also be interested in...



Amicus Reports Positive Phase II Findings For Fabry Disease Candidate Amigal

Migalastat probably is approvable, but the threat to Genzyme’s Fabrazyme is still nominal, analysts say.

Shire Shores Up Rare Disease Portfolio With Amicus Compounds

Deal valued at up to $440 million would give the U.K. firm three pharmacological chaperone compounds that could compete with Genzyme products in Gaucher, Fabry and Pompe diseases.

Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s

Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.

Topics

UsernamePublicRestriction

Register

OM011381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel